Hosted on MSN1mon
Newronika secures FDA’s IDE to begin adaptive deep brain stimulation system trial
Newronika has received an investigational device exemption (IDE) for its adaptive deep brain stimulation (DBS) system from the US Food and Drug Administration (FDA), allowing it to begin a pivotal ...
Yahoo Finance1mon
Newronika Receives Investigational Device Exemption (IDE) from FDA to Initiate U.S. Clinical Trial of Adaptive DBS System
MILAN, Feb. 5, 2025 /PRNewswire/ -- Newronika, the developer of groundbreaking adaptive deep brain stimulation technology, is proud to announce the receipt of an Investigational Device Exemption ...
Yahoo Finance29d
Newronika Closes €13.6 Million Series B Financing to Accelerate Development of Adaptive DBS Platform
MILAN, Feb. 13, 2025 /PRNewswire/ -- Newronika, a global leader in advanced deep brain stimulation, is pleased to announce the successful closing of its €13.6 million Series B funding round.
BioWorld1mon
Newronika gets IDE from the FDA for adaptive DBS trial
Newronika SpA's AlphaDBS recently secured an investigational device exemption from the U.S. FDA allowing it to begin a pivotal trial to evaluate the safety and efficacy of its adaptive deep brain ...